Prices paid for the same services vary significantly even within the same market yet, consumers often lack access to information about price and quality when seeking medical care, and providers are not required to justify higher prices with evidence of better quality. Reference pricing can motivate providers to compete based on price as well as quality, and to pursue cost-reducing innovations. The Berkeley Center for Health Technology (BCHT) conducts reference pricing research in order to identify and refine methods to control health care spending while insuring access and quality.
Reference Pricing is an insurance benefit design that:
- Encourages enrollees to favor providers charging low prices for non-emergency “shoppable” surgical procedures, diagnostic tests, and pharmaceuticals
- Can supplement or substitute for annual deductibles in health insurance
- Can motivate providers to compete based on quality and price
- Can motivate providers to pursue cost-reducing innovations
- Requires access to information on price and quality to be effective
This project analyzes pharmaceutical reference pricing initiatives currently underway in the US as they extend into new patient populations and therapeutic categories. ”Reference Pricing as a Purchasing Strategy to Promote Cost-Effective Drug Choice“ examines the extension of economic incentives to broader employer and labor union populations, compared to those previously studied. While drug reference pricing has focused primarily on retail patient-administered drugs (‘therapeutic reference pricing’), the project also will study the application of economic incentives to physician-administered (infused) specialty drugs. Reference pricing is an insurance benefit design under which consumers have access to the low-cost drugs in each therapeutic category for nominal copayments, but must pay the full difference in price if they and their physicians select more expensive therapeutically equivalent products. Patients needing a more expensive drug for appropriate clinical reasons are exempted from the additional out-of-pocket payments. This project is funded by the Laura and John Arnold Foundation.
Beginning in 2010 and 2011, the California Public Employees' Retirement System (CalPERS) established reference pricing (providing full coverage up to a defined contribution limit while requiring the patient to pay the difference between this limit and the actual price paid) for five high-cost procedures based on the state-wide distribution of prices, available information on quality, and the geographical availability of services. These procedures include hip replacement surgery, knee replacement surgery, arthroscopic surgery, cataract surgery, and colonoscopy. For reference pricing to be fully effective, individuals should not face a quality difference in the services they receive based on the type of facility in which they receive services. To ascertain the existence of quality differences and related questions, this study evaluates the impact of the CalPERS reference pricing initiative on surgical complications, consumer cost sharing and insurer payment. The study uses 2009-14 data from the nation’s largest private health insurer, Anthem Inc., and is jointly funded by CalPERS and the Agency for Health Care Research and Quality (R01 HS022098).
Economic Incentives and Consumer Choice
Reference Pricing in Germany: Implications for U.S. Pharmaceutical Purchasing. Robinson JC, Panteli D, Ex P., Commonwealth Fund, issue brief, February 2019. Issue Brief
Paying Patients To Switch: Impact Of A Rewards Program On Choice Of Providers, Prices, And Utilization. Christopher M. Whaley, Lan Vu, Neeraj Sood, Michael E. Chernew, Leanne Metcalfe, Ateev Mehrotra,10.1377/hlthaff.2018.05068 , HEALTH AFFAIRS 38, NO. 3 (2019): 440–447.
How Can We Increase Patient Shopping for High-Value Providers? Christopher M Whaley, Timothy T Brown, James C Robinson, NIHCM, Issue Brief; in press.
Firm responses to targeted consumer incentives: Evidence from reference pricing for surgical services. Christopher M Whaley, Timothy T Brown, Journal of Health Economics 61 (2018) 111–133.
How Do Providers Respond to Reference Pricing? Christopher M Whaley, Timothy T Brown, NIHCM, Issue Brief; 2018.
Pharmaceutical Reference Pricing: Does It Have a Future in the US?, Robinson JC. Commonwealth Fund, issue brief, September 2018. Issue Brief
Consumer Responses to Price Transparency Alone Versus Price Transparency Combined with Reference Pricing, Whaley C, Brown TT, Robinson JC. , American Journal of Health Economics 2018; in press.
The moral hazard effects of consumer responses to targeted cost-sharing Christopher M. Whaley, Chaoran Guo, Timothy T. Brown, Journal of Health Economics, Volume 56, December 2017, Pages 201-221
Reference Pricing, Consumer Cost-Sharing, and Insurer
Spending for Pharmaceuticals James C. Robinson, Christopher M. Whaley, and Timothy T. Brown; May 2017, Issue Brief
Impact of Reference Pricing on Patient Choices, Employer Spending and Consumer Cost Sharing in Health Insurance: Overview James C. Robinson, Christopher M. Whaley, and Timothy T. Brown; May 2017, Issue Brief
Reference Pricing Changes The ‘Choice Architecture’ Of Health Care For Consumers James C. Robinson, Timothy T. Brown, and Christopher Whaley Health Affairs; 2017; 36(3): 524–530
Reference Pricing, Consumer Cost-Sharing, and Insurer Spending for Laboratory Tests James C. Robinson, Christopher M. Whaley, and Timothy T. Brown; February 2017, Issue Brief
Reference Pricing Reduces Employer and Employee Spending for Magnetic Resonance Imaging (MRI) Scans James C. Robinson, Christopher M. Whaley, and Timothy T. Brown; October 2016, Issue Brief
Reference Pricing, Consumer Cost-Sharing, and Insurer Spending for Computed Tomography (CT) Scans James C. Robinson, Christopher M. Whaley, and Timothy T. Brown; November 2016, Issue Brief
Association of Reference Pricing for Diagnostic Laboratory Testing With Changes in Patient Choices, Prices, and Total Spending for DiagnosticTests James C. Robinson, PhD; Christopher Whaley, BA; Timothy T. Brown, PhD; JAMA Intern Med. doi:10.1001/jamainternmed.2016.2492; online July 25, 2016.
Reference Pricing, Consumer Cost Sharing, and Insurer Spending for Advanced Imaging Tests. Robinson JC, Whaley C, Brown TT; Med Care; 2016
Consumer Choice Between Hospital-Based and Freestanding Facilities for Arthroscopy. James C. Robinson, PhD; Timothy T. Brown, PhD; Christopher Whaley, PhD; Kevin J. Bozic, MD, MBA; J Bone Joint Surg Am, 2015 Sep 16; 97 (18): 1473 -1481.
Association of Reference Payment for Colonoscopy With Consumer Choices, Insurer Spending, and Procedural Complications. James C. Robinson, PhD ; Timothy T. Brown, PhD ; Christopher Whaley, PhD ; Emily Finlayson, MD, MS; JAMA Intern Med. Published online September 08, 2015. doi:10.1001/jamainternmed.2015.4594
Reference-based Benefit Design Changes Consumers’ Choices and Employers’ Payments for Ambulatory Surgery.Robinson JC, Brown TT, Whaley C; Health Affairs 2015;
Appropriate Use Of Reference Pricing Can Increase Value. Boynton A, Robinson JC; Health Affairs Blog, July 2015.
Brown TT, Robinson JC. Reference Pricing with Endogenous or Exogenous Payment Limits: Impacts on Insurer and Consumer Spending. Health Economics. Early View. Article first published online: 22 Apr1l 2015 | DOI: 10.1002/hec.3181.
Association Between Availability of Health Service Prices and Payments for These Services. Christopher Whaley, et al; JAMA, 2014; 312(16):1670-1676
Reference Pricing: Stimulating Cost-Conscious Purchasing and Countering Provider Market Power. James Robinson;National Institute for Health Care Management (NIHCM) Foundation: Expert Voices; October, 2013.
Comparison Shopping for Knee Surgery. James Robinson; Wall Street Journal; October 27, 2013.
How to Turn Employees into Value Shoppers for Health Care. James Robinson; Harvard Business Review; October 21, 2013.
Increases in Consumer Cost Sharing Redirect Patient Volumes and Reduce Hospital Prices for Orthopedic Surgery. James Robinson and Timothy Brown; Health Affairs; 2013; 32(8):1392-97.
Payment and Pricing for Innovative Pharmaceuticals
Value-based Payment for Oncology Services in the United States and France, Robinson JC, Megerlin F. Journal of Cancer Policy 2016; http://dx.doi.org/10.1016/j.jcpo.2016.09.001(link is external).
Biomedical Innovation in the Era of Health Care Spending Constraints.Robinson JC; Health Affairs 2015; 34(2):203-09.
Specialty Pharmaceuticals: Policy Initiatives to Improve Assessment, Pricing, Prescription, and Use. James Robinson and Scott Howell; Health Affairs, 2014; 33(10):1745-1750.
Robinson JC, Megerlin F. Le Rapport Prix/Valeur des Médicaments d’Oncologie a L’épreuve des Méthodes de Paiement aux États-Unis. Techniques Hospitalieres 2014; Nov-Dec: 27-35.
Payment and Purchasing for Medical Devices
Purchasing Medical Innovation: The Right Technology, for the Right Patient, at the Right Price.(link is external)(link is external) Robinson JC; University of California Press, 2015.
US Hospital Payment Adjustments for Innovative Technology Lag Behind Those In Germany, France, and Japan. Hernandez J, Machacz SF, Robinson JC; Health Affairs 2015; 34(2):261-270.
Quantifying Opportunities for Hospital Cost Control: Medical Device Purchasing and Patient Discharge Planning. Robinson JC, Brown TT; American Journal of Managed Care 2014; 20(9):e418-e424.